The Enhanced Liver Fibrosis (ELF) test is a valuable tool for detecting progression to advanced fibrosis in MASLD.

The Enhanced Liver Fibrosis (ELF) is the first prognostic tool for patients with advanced fibrosis (F3 or F4) due to non-alcoholic steatohepatitis (NASH) to be granted De Novo marketing authorization.

At present, transient elastography and the serum marker FibroTest are the most intensively evaluated non-invasive methods for the assessment of liver fibrosis. The results of the present study for ...

The Enhanced Liver Fibrosis (ELF) Test from Siemens Healthineers is now available in the United States, providing broad clinical access to the minimally invasive prognostic tool. Currently, the ELF ...

Disclaimer: The products/features (mentioned herein) are not commercially available in all countries. Their future availability cannot be guaranteed. In the U.S., the ELF Test is indicated as a ...

Data from the Non-Invasive Biomarkers of Metabolic Liver Disease (NIMBLE) study indicates Siemens Healthineers’ ELF Test as the top-performing biomarker NIMBLE, the largest biomarker consortium from ...

Siemens Healthineers is a paid sponsor of The Morning Blend. The U.S. is in the midst of a liver disease epidemic, but a new test may help turn the tide by leading to early detection of patients who ...

Background: FibroTest (FT) is the most frequently used serum fibrosis marker and consists of an algorithm of five fibrosis markers (alfa2-macroglobulin, apolipoproteinA1, haptoglobin, GGT, bilirubin).